THC vs UHS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
THC is the larger of the two ($20.94B market cap): the incumbent the market prices for continued execution (12.92x forward earnings, beta 1.20). UHS is the smaller challenger ($10.32B), cheaper on forward earnings (7.77x): more room to run, but more to prove. If you believe THC earns its premium (12.92x forward earnings, so the market expects more from it), THC fits. If you believe in paying less for profit, UHS fits at 7.77x.
THC vs UHS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | THC | UHS | What it tells you |
|---|---|---|---|
| Market cap | $20.94B | $10.32B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 12.92 | 7.77 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 7.67 | 7.49 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.20 | 1.11 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 73% of range | 37% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.85 | 1.36 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: UHS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how THC and UHS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. THC and UHS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined THC and UHS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Tenet Healthcare (THC) do?
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems.
What does Universal Health Services (UHS) do?
Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. Its two core segments are acute care, which covers general hospitals and emergency and surgical services, and behavioral health, which spans inpatient psychiatric and addiction treatment facilities where UHS is one of the largest operators in the country. The company also expanded its virtual behavioral health reach through the acquisition of Talkspace, and in November 2026 coverage focused on its growing outpatient behavioral health footprint.
THC vs UHS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- THC drivers: USPI ambulatory surgery leadership; Business mix shift toward higher-margin services.
- UHS drivers: Behavioral health scale; Acute care volumes and pricing.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. For UHS, the largest risks are tied to government reimbursement.
THC or UHS: which should you pick?
If the story you believe is THC's (USPI ambulatory surgery leadership), THC is the more direct way to own it; if it is UHS's (Behavioral health scale), UHS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the THC and UHS guides.
THC vs UHS: the full fundamentals
THC. Tenet still trades at a modest earnings multiple typical of hospital operators (a discount that prices in reimbursement and leverage risk), even after a 32% rise in 2026 as USPI mix shift, margin gains, and deleveraging improved earnings quality. The forward P/E near 12.9x sits well above the trailing 7.7x because analysts expect 2027 EPS of about $20.36, down from about $22.53 in 2026, after a run of large beats. Fourth-quarter consensus is about $5.24 of EPS on $5.67 billion of revenue, and the average of 22 analyst targets is about $309.
UHS. UHS trades at about 7.5 times trailing earnings and roughly 6.1 times EV/EBITDA, well below broader market averages, with a price-to-sales ratio near 0.56. The discount reflects caution around reimbursement and policy exposure and flat expected earnings for 2027, since revenue is still growing about 5 percent a year. The 17 covering analysts have a mean target near $197, and in November 2026 RBC raised its target to $207 and Mizuho to $225.
Headline figures (approximate, November 2026): THC shows revenue (ttm) ~$22.2 billion (Q3 2026 +~6.5% yoy), q3 2026 adjusted eps ~$6.64 vs ~$4.68 est., net income (ttm) ~$2.9 billion (net margin ~13%), operating margin (ttm) ~19%; UHS shows revenue (ttm) ~$18.35B (Q3 2026 up ~5.3% YoY), net income (ttm) ~$1.46B (profit margin ~8.0%), eps (ttm) ~$23.89, q3 2026 Revenue ~$4.73B, EPS ~$5.22 vs ~$5.15 est..
The bottom line: THC vs UHS
THC and UHS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined THC and UHS exposure against your real portfolio. It is not an investment adviser.
Wondering how THC or UHS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Tenet Healthcare
Ask Walnut's AI anything about THC and see how it fits what you own.
FAQ
What is the difference between THC and UHS?
+
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is THC or UHS the better stock?
+
Neither is universally better. THC is the larger incumbent; UHS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, THC or UHS?
+
On forward P/E (as of November 2026), THC trades at 12.92x and UHS at 7.77x, so UHS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both THC and UHS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of THC vs UHS?
+
THC: Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, about $13.2 billion at the end of September 2026, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks; peer Community Health Systems said in November 2026 that it sees patients delaying surgeries into next year as costs squeeze them. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices. After a roughly 32% gain in 2026, expectations are higher too: consensus calls for 2027 EPS of about $20.36, about 10% below the roughly $22.53 expected for 2026, so the market is not pricing in another year of earnings growth, and a stumble against that bar could weigh on the shares. The trailing P/E near 8x also flatters the stock, because the trailing $2.9 billion of net income runs well ahead of what analysts expect to recur. UHS: The largest risks are tied to government reimbursement. A meaningful share of UHS revenue comes from Medicare and Medicaid, so changes to those programs, state Medicaid supplemental payment structures, or federal healthcare policy can move earnings materially. Reporting in November 2026 pointed to lower Medicaid supplemental payments in 2027. Labor costs, including nursing wages and contract labor, remain a swing factor for margins. The behavioral health segment carries regulatory, staffing, and reputational scrutiny given the nature of inpatient psychiatric care. Rising interest expense on debt and integration risk from acquisitions such as Talkspace add further uncertainty. Analysts expect fourth-quarter EPS of about $5.61, down roughly 4.7 percent from a year earlier, and full-year 2027 EPS of about $23.03, only slightly above 2026. Free cash flow of about $745 million over the trailing year was about half of net income, and debt stood near $6.2 billion against about $169 million of cash.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell THC or UHS; figures are approximate and dated (as of November 2026). Verify current data before investing.